TWI649083B - 用於治療或預防乾眼症的方法 - Google Patents
用於治療或預防乾眼症的方法 Download PDFInfo
- Publication number
- TWI649083B TWI649083B TW105118931A TW105118931A TWI649083B TW I649083 B TWI649083 B TW I649083B TW 105118931 A TW105118931 A TW 105118931A TW 105118931 A TW105118931 A TW 105118931A TW I649083 B TWI649083 B TW I649083B
- Authority
- TW
- Taiwan
- Prior art keywords
- dry eye
- compound
- general formula
- treating
- eye
- Prior art date
Links
- 208000003556 Dry Eye Syndromes Diseases 0.000 title claims abstract description 37
- 206010013774 Dry eye Diseases 0.000 title claims abstract description 34
- 238000000034 method Methods 0.000 title abstract description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 30
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 5
- 239000008103 glucose Substances 0.000 claims abstract description 5
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims abstract description 4
- 210000001508 eye Anatomy 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 3
- 238000011200 topical administration Methods 0.000 claims 1
- JAYVHSBYKLLDJC-DSNJPTTOSA-N (E)-2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(O)C=C(O)C=C1\C=C\C1=CC=C(O)C=C1 JAYVHSBYKLLDJC-DSNJPTTOSA-N 0.000 abstract 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 14
- 102000015336 Nerve Growth Factor Human genes 0.000 description 14
- 229940053128 nerve growth factor Drugs 0.000 description 11
- 230000028327 secretion Effects 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- TXDLNDSQBXCXKE-UHFFFAOYSA-N azane;chloromethylbenzene Chemical compound N.ClCC1=CC=CC=C1 TXDLNDSQBXCXKE-UHFFFAOYSA-N 0.000 description 9
- 238000011282 treatment Methods 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 229940126062 Compound A Drugs 0.000 description 5
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 5
- 210000004561 lacrimal apparatus Anatomy 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- XKXHCNPAFAXVRZ-UHFFFAOYSA-N benzylazanium;chloride Chemical compound [Cl-].[NH3+]CC1=CC=CC=C1 XKXHCNPAFAXVRZ-UHFFFAOYSA-N 0.000 description 3
- 210000005252 bulbus oculi Anatomy 0.000 description 3
- 230000005779 cell damage Effects 0.000 description 3
- 208000037887 cell injury Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000003889 eye drop Substances 0.000 description 3
- 229940012356 eye drops Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- -1 2,3,5,4'-tetrahydroxystilbene 2-O-β-D-glucopyranoside compound Chemical class 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 210000002175 goblet cell Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010002261 Androgen deficiency Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000009043 Chemical Burns Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000028006 Corneal injury Diseases 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 101000801254 Homo sapiens Tumor necrosis factor receptor superfamily member 16 Proteins 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 101150064037 NGF gene Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003732 agents acting on the eye Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 239000000607 artificial tear Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000002038 chemiluminescence detection Methods 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000003560 epithelium corneal Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 208000001936 exophthalmos Diseases 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000000256 facial nerve Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940023490 ophthalmic product Drugs 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000003901 trigeminal nerve Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562180450P | 2015-06-16 | 2015-06-16 | |
| US62/180,450 | 2015-06-16 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201717965A TW201717965A (zh) | 2017-06-01 |
| TWI649083B true TWI649083B (zh) | 2019-02-01 |
Family
ID=57544797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW105118931A TWI649083B (zh) | 2015-06-16 | 2016-06-16 | 用於治療或預防乾眼症的方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10383885B2 (enExample) |
| EP (1) | EP3310361B1 (enExample) |
| JP (1) | JP6960399B2 (enExample) |
| KR (1) | KR102606948B1 (enExample) |
| CN (1) | CN107921053B (enExample) |
| AU (1) | AU2016279139B2 (enExample) |
| CA (1) | CA2989341C (enExample) |
| TW (1) | TWI649083B (enExample) |
| WO (1) | WO2016201953A1 (enExample) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1539844A (zh) * | 2003-10-24 | 2004-10-27 | 广州中医药大学热带医学研究所 | 降血脂药用2，3，5，4＇-四羟基二苯乙烯－2－O－β－D－葡萄糖苷 |
| CN102316873A (zh) * | 2008-12-24 | 2012-01-11 | 吴淑芬 | 促进红细胞生成的化合物和方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1332726A (zh) | 1998-11-02 | 2002-01-23 | 卫福有限公司 | 吡咯烷化合物及其药物用途 |
| CA2383971A1 (en) | 1999-09-06 | 2001-03-15 | Hiroaki Naka | Prophylactic and therapeutic medicaments for ophthalmic diseases |
| US20060292099A1 (en) * | 2005-05-25 | 2006-12-28 | Michael Milburn | Treatment of eye disorders with sirtuin modulators |
| CN101966193B (zh) * | 2010-10-29 | 2012-05-23 | 西南交通大学 | 2,3,5,4’-四羟基二苯乙烯-2-O-β-D-葡萄糖苷在制备治疗抑郁症药物中的应用 |
| US20120164242A1 (en) * | 2010-12-27 | 2012-06-28 | Wen-Jen Yu | Novel methods for modulating melanin production |
| CN105188688A (zh) * | 2013-03-28 | 2015-12-23 | 吴淑芬 | 用于在非造血性细胞中诱导促红细胞生成素(epo)介导的产生血红蛋白表达和线粒体生物合成的组合物和方法 |
| CN103524576A (zh) * | 2013-08-12 | 2014-01-22 | 天津中医药大学 | 2,3,5,4′-四羟基二苯乙烯-2-O-β-D-葡萄糖苷的分离纯化工艺 |
-
2016
- 2016-06-16 EP EP16810694.6A patent/EP3310361B1/en active Active
- 2016-06-16 KR KR1020187000291A patent/KR102606948B1/ko active Active
- 2016-06-16 CA CA2989341A patent/CA2989341C/en active Active
- 2016-06-16 AU AU2016279139A patent/AU2016279139B2/en active Active
- 2016-06-16 TW TW105118931A patent/TWI649083B/zh active
- 2016-06-16 US US15/737,072 patent/US10383885B2/en active Active
- 2016-06-16 CN CN201680035333.5A patent/CN107921053B/zh active Active
- 2016-06-16 WO PCT/CN2016/000309 patent/WO2016201953A1/en not_active Ceased
- 2016-06-16 JP JP2018517468A patent/JP6960399B2/ja active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1539844A (zh) * | 2003-10-24 | 2004-10-27 | 广州中医药大学热带医学研究所 | 降血脂药用2，3，5，4＇-四羟基二苯乙烯－2－O－β－D－葡萄糖苷 |
| CN102316873A (zh) * | 2008-12-24 | 2012-01-11 | 吴淑芬 | 促进红细胞生成的化合物和方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180019151A (ko) | 2018-02-23 |
| CA2989341A1 (en) | 2016-12-22 |
| EP3310361B1 (en) | 2022-05-11 |
| CN107921053B (zh) | 2020-09-01 |
| US20180193369A1 (en) | 2018-07-12 |
| AU2016279139B2 (en) | 2020-09-10 |
| US10383885B2 (en) | 2019-08-20 |
| AU2016279139A1 (en) | 2018-01-04 |
| WO2016201953A1 (en) | 2016-12-22 |
| CA2989341C (en) | 2021-12-07 |
| CN107921053A (zh) | 2018-04-17 |
| JP2018517776A (ja) | 2018-07-05 |
| EP3310361A4 (en) | 2019-01-23 |
| KR102606948B1 (ko) | 2023-11-27 |
| EP3310361A1 (en) | 2018-04-25 |
| TW201717965A (zh) | 2017-06-01 |
| JP6960399B2 (ja) | 2021-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9925201B2 (en) | Compositions and treatment for eye diseases and disorders | |
| KR102578102B1 (ko) | 엔도텔린 수용체 길항제의 국소 안용 제형 | |
| US10010586B2 (en) | Method of treating intraocular tissue pathologies with nerve growth factor | |
| CN107735091A (zh) | 包含伊马替尼作为活性成分的用于预防和治疗干眼病的药物组合物 | |
| WO2020231670A1 (en) | Triamcinolone acetonide-loaded liposomes topical ophthalmic formulations for prevention of macular thickening and its associated visual outcomes after lens surgery | |
| WO2012068998A2 (zh) | 一种曲安奈德眼用制剂及其制备方法 | |
| WO2020219475A1 (en) | Compositions and methods useable for treatment of dry eye | |
| CN107921053B (zh) | 用于治疗或预防干眼症的方法 | |
| JP7637430B2 (ja) | 新規な眼球乾燥症治療用薬学的組成物 | |
| JP2023518179A (ja) | ドライアイ疾患、網膜変性疾患、又は眼の炎症の治療のための抗老化グリコペプチドの使用 | |
| WO2025140240A1 (zh) | 一种用于治疗和/或预防角膜损伤的药物组合物和方法 | |
| Chen et al. | P2X4 Receptor Antagonist Ameliorates Ocular Pain in Rats After Lacrimal Gland Removal | |
| KR20250023387A (ko) | 안구 건조증 질환 치료를 위한 pedf 유래 짧은 펩타이드를 포함하는 조성물 | |
| CN111632128A (zh) | 短链胜肽组合物在预防或治疗干眼症的应用 | |
| Daull et al. | Cationic oil‐in‐water emulsions protect and restore function of the injured ocular surface | |
| Motterle | Management of Ocular Allergy | |
| Koçluk et al. | Ceratoconjuntivite atópica: resultados a longo prazo do tratamento clínico e da ceratoplastia penetrante |